- Home
- NEGG vs ABOS Comparison
NEGG vs ABOS Comparison
Compare NEGG & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEGG
- ABOS
- Stock Information
- Founded
- NEGG 2001
- ABOS 1996
- Country
- NEGG United States
- ABOS United States
- Employees
- NEGG N/A
- ABOS N/A
- Industry
- NEGG Other Specialty Stores
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- NEGG Consumer Discretionary
- ABOS Health Care
- Exchange
- NEGG Nasdaq
- ABOS Nasdaq
- Market Cap
- NEGG 122.3M
- ABOS 113.9M
- IPO Year
- NEGG 2010
- ABOS 2021
- Fundamental
- Price
- NEGG $77.77
- ABOS $1.94
- Analyst Decision
- NEGG
- ABOS Strong Buy
- Analyst Count
- NEGG 0
- ABOS 3
- Target Price
- NEGG N/A
- ABOS $8.00
- AVG Volume (30 Days)
- NEGG 1.2M
- ABOS 392.7K
- Earning Date
- NEGG 12-01-2025
- ABOS 11-11-2025
- Dividend Yield
- NEGG N/A
- ABOS N/A
- EPS Growth
- NEGG N/A
- ABOS N/A
- EPS
- NEGG N/A
- ABOS N/A
- Revenue
- NEGG $1,313,127,000.00
- ABOS N/A
- Revenue This Year
- NEGG N/A
- ABOS N/A
- Revenue Next Year
- NEGG N/A
- ABOS N/A
- P/E Ratio
- NEGG N/A
- ABOS N/A
- Revenue Growth
- NEGG N/A
- ABOS N/A
- 52 Week Low
- NEGG $3.32
- ABOS $0.86
- 52 Week High
- NEGG $137.84
- ABOS $3.36
- Technical
- Relative Strength Index (RSI)
- NEGG 64.60
- ABOS 47.55
- Support Level
- NEGG $43.00
- ABOS $1.85
- Resistance Level
- NEGG $87.20
- ABOS $2.46
- Average True Range (ATR)
- NEGG 8.96
- ABOS 0.19
- MACD
- NEGG 3.31
- ABOS -0.03
- Stochastic Oscillator
- NEGG 78.66
- ABOS 14.75
About NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally. Geographically, it operates in United States, Canada, and Rest of World.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.